Literature DB >> 17880609

Complications of apheresis in children.

Bruno Michon1, Albert Moghrabi, Rochelle Winikoff, Stéphane Barrette, Mark L Bernstein, Josette Champagne, Michèle David, Michel Duval, Heather A Hume, Nancy Robitaille, André Bélisle, Martin A Champagne.   

Abstract

BACKGROUND: Although the frequency of complications in adults undergoing therapeutic apheresis is low, there are little data in children. STUDY DESIGN AND METHODS: A retrospective study of 186 children who had undergone a total of 1632 apheresis procedures between 1994 and 2002 was conducted. Adverse reactions were prospectively documented. The procedures were plasma exchange (67%), hematopoietic progenitor cell collection (18%), red blood cell exchange (6.9%), leukodepletion (0.7%), and plasma exchange with immunoadsorption (6.7%).
RESULTS: Adverse reactions, most minor, were reported in 55 percent of procedures in 82 percent of patients. The most frequent complications, per procedure and per patient during an entire course of therapy, were hypotension (14 and 48.4%), hypotension requiring fluid bolus (4.8 and 26.9%), symptomatic hypocalcemia (9.7 and 28.5%), allergic reactions (4.4 and 5.9%), catheter-related thrombosis (1.7 and 12.4%), catheter-related infection (2.1 and 16.1%), and severe anemia (hemoglobin [Hb] level, <7 g/dL; 2.5 and 17.2%). There were two deaths (1% of patients). Risk factors for complications by multivariate analysis were lower body weight, lower preapheresis Hb level, apheresis in a critical care unit, and number of procedures per patient. The 55 percent incidence of complications per procedure in our pediatric cohort is much higher than the 4.3 to 28 percent incidence reported in adults. The excess of adverse reactions in children are mostly related to citrate toxicity, higher relative vascular volume shifts, and the need for vascular access.
CONCLUSION: Pediatric apheresis presents unique challenges and is associated with higher complication rate compared to adults. It is recommended that this procedure be performed in specialized centers.

Entities:  

Mesh:

Year:  2007        PMID: 17880609     DOI: 10.1111/j.1537-2995.2007.01405.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  30 in total

1.  Analysis and management of the risks related to the collection, processing and distribution of peripheral blood haematopoietic stem cells.

Authors:  Franco Bambi; Irene Spitaleri; Gianluca Verdolini; Stefania Gianassi; Alessandro Perri; Fabrizio Dori; Ernesto Iadanza
Journal:  Blood Transfus       Date:  2009-01       Impact factor: 3.443

Review 2.  Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013.

Authors:  Caitlin E Carter; Nadine M Benador
Journal:  Pediatr Nephrol       Date:  2013-06-29       Impact factor: 3.714

3.  Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.

Authors:  Gema Ariceta; Nesrin Besbas; Sally Johnson; Diana Karpman; Daniel Landau; Christoph Licht; Chantal Loirat; Carmine Pecoraro; C Mark Taylor; Nicole Van de Kar; Johan Vandewalle; Lothar B Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-09-18       Impact factor: 3.714

4.  Renal failure, respiratory distress, and an atypical purpuric rash in a full-term infant with omphalocele and hypospadias: Answers.

Authors:  Aaron J Weiss; Kenny Kronforst
Journal:  Pediatr Nephrol       Date:  2019-06-24       Impact factor: 3.714

5.  Atypical hemolytic uremic syndrome with MCP mutations preceded by respiratory infection.

Authors:  Keiko Yasuda; Koichi Sasaki; Masaya Yamato; Hiromi Rakugi; Yoshitaka Isaka; Terumasa Hayashi; Rossella Piras; Elena Bresin
Journal:  CEN Case Rep       Date:  2012-10-05

Review 6.  Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.

Authors:  Julien Zuber; Fadi Fakhouri; Lubka T Roumenina; Chantal Loirat; Véronique Frémeaux-Bacchi
Journal:  Nat Rev Nephrol       Date:  2012-10-02       Impact factor: 28.314

7.  First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients.

Authors:  Selçuk Yüksel; Havva Evrengül; Z Birsin Özçakar; Tülay Becerir; Nagihan Yalçın; Emine Korkmaz; Fatih Ozaltin
Journal:  Paediatr Drugs       Date:  2016-12       Impact factor: 3.022

8.  Indications, technique, and outcome of therapeutic apheresis in European pediatric nephrology units.

Authors:  Fabio Paglialonga; Claus Peter Schmitt; Rukshana Shroff; Karel Vondrak; Christoph Aufricht; Alan Rees Watson; Gema Ariceta; Michael Fischbach; Gunter Klaus; Tuula Holtta; Sevcan A Bakkaloglu; Alexandra Zurowska; Augustina Jankauskiene; Johan Vande Walle; Betti Schaefer; Elizabeth Wright; Roy Connell; Alberto Edefonti
Journal:  Pediatr Nephrol       Date:  2014-08-20       Impact factor: 3.714

9.  Leukapheresis protocol for nonhuman primates weighing less than 10 kg.

Authors:  Vimukthi Pathiraja; Abraham J Matar; Ashley Gusha; Christene A Huang; Raimon Duran-Struuck
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-01       Impact factor: 1.232

10.  Role of therapeutic apheresis in the treatment of pediatric kidney diseases.

Authors:  Shweta Shah; Catherine Joseph; Poyyapakkam Srivaths
Journal:  Pediatr Nephrol       Date:  2021-05-15       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.